BRAF V600E在成釉细胞瘤、成釉细胞癌和囊肿中的表达

doi:10.19439/j.sjos.2023.06.012

上海口腔医学 ›› 2023, Vol. 32 ›› Issue (6): 630-634.doi: 10.19439/j.sjos.2023.06.012

BRAF V600E在成釉细胞瘤、成釉细胞癌和囊肿中的表达

裴婧¹, 张林², 贾云香¹, 陈蔚华¹

1.南昌大学附属口腔医院病理科,2.修复科,江西省口腔生物医学重点实验室, 江西省口腔疾病临床医学研究中心,江西南昌 330006

收稿日期:2022-11-08 修回日期:2023-01-15 出版日期:2023-12-15 发布日期:2024-01-12
通讯作者: 陈蔚华,E-mail: 450658573@qq.com
作者简介:裴婧(1984-),女,硕士,副主任医师,E-mail: peijingzi@163.com
基金资助:
江西省卫生健康委员会科技计划（20204404）

BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts

PEI Jing¹, ZHANG Lin², JIA Yun-xiang¹, CHEN Wei-hua¹

1. Department of Pathology, 2. Department of Prosthodontics, Affiliated Stomatological Hospital of Nanchang University; Key Laboratory of Oral Biomedicine, Jiangxi Province; Jiangxi Province Clinical Research Center for Oral Diseases. Nanchang 330006, Jiangxi Province, China

Received:2022-11-08 Revised:2023-01-15 Online:2023-12-15 Published:2024-01-12

摘要/Abstract

摘要： 目的: 探讨BRAF V600E表达是否与成釉细胞瘤复发、恶变有关。方法: 运用免疫组织化学和实时荧光定量PCR（qPCR）检测成釉细胞瘤、成釉细胞癌、囊肿中BRAF V600E的蛋白和基因表达水平。采用SPSS 26.0软件包对数据进行统计学分析。结果: BRAF V600E在原发性成釉细胞瘤和复发性成釉细胞瘤中的表达无显著差异,在囊肿和成釉细胞癌中的表达显著减少。免疫组织化学和RT-qPCR检测的阳性率一致。结论: 成釉细胞瘤中BRAF V600E的蛋白表达与年龄、性别、部位、大小、组织学类型以及是否复发无关,BRAF V600E的表达对鉴别成釉细胞瘤、囊肿、成釉细胞癌有一定指导意义。使用免疫组织化学方法或许能初步检测成釉细胞瘤中是否存在BRAF突变。

关键词: 成釉细胞瘤, 成釉细胞癌, BRAF V600E, 复发

Abstract: PURPOSE: To investigate protein and genetic status of BRAF V600E in ameloblastomas, ameloblastic carcinomas and cysts, and to explore if recurrence and malignant transformation of ameloblastomas depends on BRAF status. METHODS: Twenty cysts, 25 primary ameloblastomas, 25 recurrent ameloblastomas and 8 ameloblastic carcinomas were analysed by immunohistochemistry, and 2 cysts, 5 primary ameloblatomas, 5 recurrent ameloblastomas, 3 atypical ameloblastomas and 6 ameloblastic carcinomas were analysed by quantitative real-time PCR(qPCR). SPSS 26.0 software package was used for data analysis. RESULTS: There was no correlation between BRAF V600E expression and recurrence. Cysts and carcinomas had lower frequencies of BRAF V600E mutations than ameloblastomas. There was a concordance between positive staining of BRAF V600E protein and BRAF V600E mutation. CONCLUSIONS: BRAF V600E mutation may be useful in the differential diagnosis of ameloblastomas with cysts and ameloblastic carcinomas. Immunohistochemistry may be a beneficial method to screen for BRAF V600E mutation in ameloblastoma.

Key words: Ameloblastoma, Ameloblastic carcinoma, BRAF V600E, Recurrence

中图分类号:

R739.8

裴婧, 张林, 贾云香, 陈蔚华. BRAF V600E在成釉细胞瘤、成釉细胞癌和囊肿中的表达[J]. 上海口腔医学, 2023, 32(6): 630-634.

PEI Jing, ZHANG Lin, JIA Yun-xiang, CHEN Wei-hua. BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts[J]. Shanghai Journal of Stomatology, 2023, 32(6): 630-634.

参考文献

[1] Brown NA, Rolland D, McHugh JB, et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma[J] Clin Cancer Res, 2014, 20(21): 5517-5526.
[2] Capper D, Preusser M, Habel A, et al.Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody[J]. Acta Neuropathol, 2011, 122(1): 11-19.
[3] Fernandes GS, Girardi DM, Bernardes JPG, et al.Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation[J]. BMC Cancer, 2018, 18(1): 887-892.
[4] Tan S, Pollack JR, Kaplan MJ, et al.BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(1): e5-e7.
[5] Derakhshan S, Aminishakib P, Karimi A, et al.High frequency of BRAF V600E mutation in Iranian population ameloblastomas[J]. Med Oral Patol Oral Cir Bucal, 2020, 25(4): e502-e507.
[6] Yang R, Liu Z, Gokavarapu S, et al.Recurrence and cancerization of ameloblastoma: multivariate analysis of 87 recurrent craniofacial ameloblastoma to assess risk factors associated with early recurrence and secondary ameloblastic carcinoma[J]. Chin J Cancer Res, 2017, 29(3): 189-195.
[7] Kelppe J, Thorén H, Ristimäki A, et al.BRAF V600E expression in ameloblastomas-a 36 patient cohort from Helsinki University Hospital[J]. Oral Dis, 2019, 25(4): 1169-1174.
[8] Seki-Soda M, Sano T, Ito K, et al.An immunohistochemical and genetic study of BRAF V600E mutation in Japanese patients with ameloblastoma[J]. Pathol Int, 2020, 70(4): 224-230.
[9] Pereira NB, Pereira KM, Coura BP, et al.BRAF V600E mutation in the diagnosis of unicystic ameloblastoma[J]. J Oral Pathol Med, 2016, 45(10): 780-785.
[10] Oh KY, Cho SD, Yoon HJ, et al.Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: comparative analysis of two VE1 antibodies[J]. J Oral Pathol Med, 2021, 50(1): 85-91.
[11] Shirsat PM, Bansal S, Prasad P, et al.Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: an institutional study[J]. J Oral Maxillofac Pathol, 2018, 22(3): 353-359.
[12] Fregnani ER, Perez DE, Paes de Almeida O, et al. BRAF-V600E expression correlates with ameloblastoma aggressiveness[J]. Histopathology, 2017, 70(3): 473-484.
[13] Sant'Ana MSP, Dos Santos Costa SF, da Silva MP, et al. BRAF p.V600E status in epithelial areas of ameloblastoma with different histological aspects: implications to the clinical practice[J]. J Oral Pathol Med, 2021, 50(5): 478-484.
[14] Zhang R, Yang Q, Qu J, et al.The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2020, 129(3): 229-235.
[15] González-González R, López-Verdín S, Lavalle-Carrasco J, et al.Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: systematic review[J]. World J Clin Oncol, 2020, 11(1): 31-42.

BRAF V600E在成釉细胞瘤、成釉细胞癌和囊肿中的表达

BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	罗号, 袁壮, 吴开柳, 贺捷, 孟箭. 92例上颌骨成釉细胞瘤不同手术方式的效果评价[J]. 上海口腔医学, 2022, 31(1): 71-74.
[2]	徐万林, 朱云, 卢浩, 丁继平, 姚原, 刘胜文, 张陈平, 杨雯君. 腮腺区广泛型复发性多形性腺瘤的面神经处理及术后放疗经验：附10例报告[J]. 上海口腔医学, 2021, 30(6): 667-672.
[3]	代书林, 王旭霞, 乜福娇, 崔群, 韩媛媛, 张君. 异普黄酮对大鼠正畸牙复发过程中牙周组织改建的影响[J]. 上海口腔医学, 2021, 30(1): 23-27.
[4]	黄丹妮, 陈文鑫, 熊浩峰, 胡鑫, 毛婷, 苏彤. 口腔鳞状细胞癌患者术后服用二甲双胍对预后的影响[J]. 上海口腔医学, 2021, 30(1): 61-65.
[5]	孙海涛, 冯小东. IL-23R基因多态性与复发性口腔溃疡易感性及临床疗效的相关性分析[J]. 上海口腔医学, 2020, 29(4): 418-422.
[6]	郑重阳, 张新宇, 曹锐, 刘浏, 胡永杰. 超声刀辅助下腮腺良性肿瘤功能性包膜外切除术的临床效果评价[J]. 上海口腔医学, 2019, 28(4): 402-407.
[7]	林琪, 谢云德, 谢清琪, 郑鑫, 崔筱薇, 赖福煊, 张志欣, 马忠雄. 复发性阿弗他溃疡相关危险因素的病例对照研究[J]. 上海口腔医学, 2019, 28(1): 53-56.
[8]	张敬, 令狐瑞琦, 沙晶晶, 胡欣培, 李丹, 李梦源. NF-κB信号转导通路与复发性口腔溃疡的相关性分析[J]. 上海口腔医学, 2018, 27(5): 513-517.
[9]	马鹏涛, 吴宁宁, 裴蓉. 康复新液联合大蒜素胶囊治疗儿童复发性口腔溃疡的疗效及对免疫调节的影响[J]. 上海口腔医学, 2018, 27(5): 526-529.
[10]	杜全高, 许亚梅, 吴婷婷, 付钢. IL-10-1082G/A基因多态性与复发性口腔溃疡易感性的meta分析[J]. 上海口腔医学, 2018, 27(5): 554-560.
[11]	洪晨, 王文梅, 王翔, 唐巍. 复发性阿弗他溃疡患者心理因素及血浆儿茶酚胺水平变化[J]. 上海口腔医学, 2018, 27(1): 48-51.
[12]	邹俐琳, 王文梅, 刘雅菁, 蒋廷旺, 王蓓丽. 顽固性复发性阿弗他溃疡患者外周血Th17细胞与免疫球蛋白及补体水平的变化[J]. 上海口腔医学, 2017, 26(5): 521-525.
[13]	郑亚楠, 陶钧, 龚茜, 唐宏. 医学院校大学生复发性阿弗他溃疡发病率及其与A型人格关系的调查分析[J]. 上海口腔医学, 2017, 26(5): 553-556.
[14]	蓝余炼, 唐亮, 崔日林. 铁代谢在复发性口腔溃疡患者中的变化及其与细胞免疫功能的关系[J]. 上海口腔医学, 2017, 26(3): 302-304.
[15]	杜岩, 邢跃雷, 季磊, 杨洋, 欧龙, 刘荣森, 张贤华. 食物特异性IgG抗体检测在轻度复发性阿弗他溃疡诊治过程中的作用[J]. 上海口腔医学, 2017, 26(3): 309-313.